1. Reduced-Dose Systemic Fibrinolysis in Massive Pulmonary Embolism: A Pilot Study
- Author
-
Ahmet Çağrı Aykan, Tayyar Gökdeniz, İlker Gül, Ezgi Kalaycıoğlu, Can Yücel Karabay, Faruk Boyacı, Engin Hatem, Scott D. Weingart, and İhsan Dursun
- Subjects
pulmonary embolism ,thrombolytic therapy ,echocardiography ,low-dose tissue plasminogen activator ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Objective Severe pulmonary embolism (PE) has a high mortality rate, which can be lowered by thrombolytic therapy (TT). However, full-dose TT is associated with major complications, including life-threatening bleeding. The aim of this study was to explore the efficacy and safety of extended, low-dose administration of tissue plasminogen activator (tPA) on in-hospital mortality and outcomes in massive PE. Methods This was a single-center, prospective cohort trial at a tertiary university hospital. A total of 37 consecutive patients with massive PE were included. A peripheral intravenous infusion was used to administer 25 mg of tPA over 6 hours. The primary endpoints were in-hospital mortality, major complications, pulmonary hypertension, and right ventricular dysfunction. The secondary endpoints were 6-month mortality and pulmonary hypertension and right ventricular dysfunction 6 months after the PE. Results The mean age of the patients was 68.76±14.54 years. The mean pulmonary artery systolic pressure (PASP; 56.51±7.34 mmHg vs. 34.16±2.81 mmHg, P
- Published
- 2023
- Full Text
- View/download PDF